跳轉至內容
Merck
  • Alzheimer's-Associated Upregulation of Mitochondria-Associated ER Membranes After Traumatic Brain Injury.

Alzheimer's-Associated Upregulation of Mitochondria-Associated ER Membranes After Traumatic Brain Injury.

Cellular and molecular neurobiology (2022-12-27)
Rishi R Agrawal, Delfina Larrea, Yimeng Xu, Lingyan Shi, Hylde Zirpoli, Leslie G Cummins, Valentina Emmanuele, Donghui Song, Taekyung D Yun, Frank P Macaluso, Wei Min, Steven G Kernie, Richard J Deckelbaum, Estela Area-Gomez
摘要

Traumatic brain injury (TBI) can lead to neurodegenerative diseases such as Alzheimer's disease (AD) through mechanisms that remain incompletely characterized. Similar to AD, TBI models present with cellular metabolic alterations and modulated cleavage of amyloid precursor protein (APP). Specifically, AD and TBI tissues display increases in amyloid-β as well as its precursor, the APP C-terminal fragment of 99 a.a. (C99). Our recent data in cell models of AD indicate that C99, due to its affinity for cholesterol, induces the formation of transient lipid raft domains in the ER known as mitochondria-associated endoplasmic reticulum (ER) membranes ("MAM" domains). The formation of these domains recruits and activates specific lipid metabolic enzymes that regulate cellular cholesterol trafficking and sphingolipid turnover. Increased C99 levels in AD cell models promote MAM formation and significantly modulate cellular lipid homeostasis. Here, these phenotypes were recapitulated in the controlled cortical impact (CCI) model of TBI in adult mice. Specifically, the injured cortex and hippocampus displayed significant increases in C99 and MAM activity, as measured by phospholipid synthesis, sphingomyelinase activity and cholesterol turnover. In addition, our cell type-specific lipidomics analyses revealed significant changes in microglial lipid composition that are consistent with the observed alterations in MAM-resident enzymes. Altogether, we propose that alterations in the regulation of MAM and relevant lipid metabolic pathways could contribute to the epidemiological connection between TBI and AD.

材料
產品編號
品牌
產品描述

Roche
不含EDTA的cOmplete Mini蛋白酶抑制剂混合物, Protease Inhibitor Cocktail Tablets provided in a glass vial, Tablets provided in a glass vial
Sigma-Aldrich
蛋白酶 K 来源于林伯氏白色念球菌, buffered aqueous glycerol solution, for molecular biology, ≥800 units/mL
Sigma-Aldrich
单克隆抗 β-肌动蛋白抗体 小鼠抗, clone AC-15, ascites fluid
Sigma-Aldrich
细胞色素 C 来源于马心脏, ≥95% (SDS-PAGE)
Sigma-Aldrich
过氧化氢酶 来源于牛肝脏, powder, suitable for cell culture, 2,000-5,000 units/mg protein
Sigma-Aldrich
抗淀粉样肽前体蛋白C-末端 兔抗, IgG fraction of antiserum, buffered aqueous solution
Sigma-Aldrich
黏着斑蛋白单克隆抗体 小鼠抗, clone VIN-11-5, ascites fluid